Clinical trials
Completed Respiration Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
204 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 8 |
| 2011 | 10 |
| 2012 | 6 |
| 2013 | 6 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 6 |
| 2017 | 17 |
| 2018 | 22 |
| 2019 | 12 |
| 2020 | 22 |
| 2021 | 18 |
| 2022 | 10 |
| 2023 | 18 |
| 2024 | 12 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 204 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 20 |
| AstraZeneca | 13 |
| R-Pharm | 3 |
| University of Zurich | 3 |
| Altesa Biosciences, Inc. | 2 |
| Centro Universitário Augusto Motta | 2 |
| Emory University | 2 |
| Göteborg University | 2 |
| ImThera Medical, Inc. | 2 |
| Istanbul University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Respiration Disorders | 204 |
| Pulmonary Disease, Chronic Obstructive | 40 |
| COVID-19 | 22 |
| Lung Diseases | 22 |
| Respiratory Tract Diseases | 15 |
| Asthma | 12 |
| Signs and Symptoms, Respiratory | 9 |
| Apnea | 8 |
| Respiratory Insufficiency | 8 |
| Sleep Apnea Syndromes | 8 |
Trials
Showing 76 to 100 of 204. Each trial links to its page on Pharma Observatory.
104 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.